5.79
+0.23(+4.14%)
Currency In USD
Address
117 Kendrick Street
Needham, MA 02494
United States of America
Phone
617 916 5445
Website
Sector
Healthcare
Industry
Biotechnology
Employees
38
First IPO Date
July 27, 2021
| Name | Title | Pay | Year Born |
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer & Director | 1.45M | 1961 |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 613,231 | 1968 |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 726,222 | 1978 |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | 0 | 1961 |
| Ms. Ileen B. Winick | Chief People Officer | 0 | N/A |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer | 0 | 1969 |
| Mr. Charles Schoch | Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary | 0 | 1985 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.